Collegium Pharmaceutical, Inc. Common Stock (COLL) is a publicly traded Healthcare sector company. As of May 21, 2026, COLL trades at $34.78 with a market cap of $1.09B and a P/E ratio of 14.45. COLL moved +1.81% today. Year to date, COLL is -25.09%; over the trailing twelve months it is +14.22%. Its 52-week range spans $23.23 to $50.79. Analyst consensus is strong buy with an average price target of $53.40. Rallies surfaces COLL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Collegium Completes $650M AZSTARYS Acquisition, Boosts 2026 Revenue Guidance to $895M: Collegium has completed its $650 million cash acquisition of AZSTARYS from Corium Therapeutics, adding a CNS stimulant that generated over 760,000 prescriptions in 2025 and carries patent protection through 2037. The company raised 2026 guidance to $865–895 million in net product revenues and $475–500 million in adjusted EBITDA, expecting $60–70 million from AZSTARYS.
| Metric | Value |
|---|---|
| Price | $34.78 |
| Market Cap | $1.09B |
| P/E Ratio | 14.45 |
| EPS | $2.37 |
| Dividend Yield | 0.00% |
| 52-Week High | $50.79 |
| 52-Week Low | $23.23 |
| Volume | 100 |
| Avg Volume | 0 |
| Revenue (TTM) | $796.33M |
| Net Income | $74.95M |
| Gross Margin | 60.68% |
6 analysts cover COLL: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $53.40.